Updating the MASH pharmacotherapy landscape: a network meta-analysis incorporating SGLT2 inhibitors and emerging combination therapies
-
By
-
Mengshi Tang
-
Yingxu Ma
-
Yating Wang
-
June 4, 2026
-
Clinical Scorecard: Revising the Pharmacotherapy Approach for MASH: A Network Meta-Analysis Featuring SGLT2 Inhibitors and New Combination Treatments
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Pharmacological agents targeting GLP-1, FGF21, THR-β, and SGLT2 pathways. |
| Target Population | |
| Care Setting | |
Key Highlights
- SGLT2 inhibitors and FGF21 analogs ranked highest for fibrosis improvement.
- SGLT2 inhibitors showed significant benefits for MASH resolution.
- GLP-1/GIP dual agonists demonstrated the highest efficacy for MASH resolution.
Guideline-Based Recommendations
Diagnosis
- Biopsy-proven diagnosis of MASH is required.
Management
- Consider pharmacological interventions targeting MASH and liver fibrosis.
Monitoring & Follow-up
- Monitor for fibrosis improvement and safety through adverse event reporting.
Risks
- Potential adverse events leading to treatment discontinuation.
Patient & Prescribing Data
Adults with biopsy-confirmed MASH and liver fibrosis.
SGLT2 inhibitors may represent a promising oral option for fibrosis improvement.
Clinical Best Practices
Related Resources & Content
